Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1948 2
1951 7
1952 2
1953 6
1954 5
1955 11
1956 6
1957 6
1958 5
1959 5
1960 6
1961 7
1962 7
1963 1
1964 4
1965 2
1966 1
1967 2
1970 1
1971 2
1972 34
1973 63
1974 55
1975 67
1976 101
1977 60
1978 85
1979 93
1980 72
1981 95
1982 120
1983 87
1984 128
1985 107
1986 118
1987 116
1988 118
1989 104
1990 109
1991 129
1992 97
1993 92
1994 105
1995 105
1996 104
1997 93
1998 82
1999 99
2000 126
2001 83
2002 80
2003 90
2004 78
2005 86
2006 81
2007 74
2008 78
2009 62
2010 81
2011 78
2012 74
2013 64
2014 64
2015 54
2016 54
2017 46
2018 54
2019 40
2020 34
2021 34
2022 34
2023 54
2024 17

Text availability

Article attribute

Article type

Publication date

PubMed (MeSH Keyword) for id: 2578

4,154 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study.
Grover NS, Hucks G, Riches ML, Ivanova A, Moore DT, Shea TC, Seegars MB, Armistead PM, Kasow KA, Beaven AW, Dittus C, Coghill JM, Jamieson KJ, Vincent BG, Wood WA, Cheng C, Morrison JK, West J, Cavallo T, Dotti G, Serody JS, Savoldo B. Grover NS, et al. Lancet Haematol. 2024 May;11(5):e358-e367. doi: 10.1016/S2352-3026(24)00064-4. Epub 2024 Mar 28. Lancet Haematol. 2024. PMID: 38555923 Clinical Trial.
Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review.
de Oliveira VA, Negreiros HA, de Sousa IGB, Farias Mendes LK, Alves Damaceno Do Lago JP, Alves de Sousa A, Alves Nobre T, Pereira IC, Carneiro da Silva FC, Lopes Magalhães J, de Castro E Sousa JM. de Oliveira VA, et al. J Toxicol Environ Health B Crit Rev. 2024 May 18;27(4):131-152. doi: 10.1080/10937404.2024.2326679. Epub 2024 Mar 13. J Toxicol Environ Health B Crit Rev. 2024. PMID: 38480528 Review.
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X, Lin L, Yang Y, Wang N, Wang J, Xu J, Wei J, Huang L, Zheng M, Xiao Y, Meng F, Cao Y, Zhu X, Zhang Y. Xin X, et al. Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19. Cytotherapy. 2024. PMID: 38385909 Free article.
4,154 results